Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | EVP, Chief Operating Officer | March 03, 2021 | March 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intellia Therapeutics, Inc.
Report date March 03, 2021 · Filed March 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.71 · Expires 2031-03-02 | Direct | 78,750 |
Reported balance
After 2021-03-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-03 · Grant · Acquired 78,750 · Balance 78,750 F1: This option was granted on March 3, 2021 with respect to 78,750 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 13,125 |
Reported balance
After 2021-03-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-03 · Grant · Acquired 13,125 · Balance 13,125 F2: On March 3, 2021, the reporting person was granted 13,125 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on March 3, 2021 with respect to 78,750 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
F2: On March 3, 2021, the reporting person was granted 13,125 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2021 Filed Mar 5, 2021 17:53 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantRestricted Stock Unit · Derivative | 13,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018326 · doc4.xml · derivative · entry 2 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 13,125 shares Expires not disclosed F2 · derivative.exercise_price: On March 3, 2021, the reporting person was granted 13,125 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. F2 · date: On March 3, 2021, the reporting person was granted 13,125 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. F2 · derivative.exercise_date: On March 3, 2021, the reporting person was granted 13,125 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. F2 · derivative.expiration_date: On March 3, 2021, the reporting person was granted 13,125 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 17:53 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 78,750 | $0.00 Strike: $57.71 | $0.00 |
DisclosureSEC source: 0001209191-21-018326 · doc4.xml · derivative · entry 1 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 78,750 shares Expires 2031-03-02 F1 · derivative.exercise_date: This option was granted on March 3, 2021 with respect to 78,750 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 05, 2021 Filed Jan 5, 2021 20:58 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,377 | $55.86 | $76,919.22 |
DisclosureSEC source: 0001209191-21-001718 · doc4.xml · nonDerivative · entry 2 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,656 F2 · kind: Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of 4,792 performance-based restricted stock units ("PRSUs") on December 31, 2020. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 20:58 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionRestricted Stock Unit (performance-based) · Derivative | 4,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001718 · doc4.xml · derivative · entry 5 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,792 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F4 · date: On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F4 · shares: On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F4 · derivative.exercise_date: On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F4 · derivative.expiration_date: On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 20:58 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantRestricted Stock Unit (performance-based) · Derivative | 4,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001718 · doc4.xml · derivative · entry 4 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,792 Underlying: Common Stock · 4,792 shares Expires not disclosed F4 · derivative.exercise_price: On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F4 · date: On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F4 · shares: On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F4 · derivative.exercise_date: On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. F4 · derivative.expiration_date: On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 20:58 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 9,583 | $0.00 Strike: $20.56 | $0.00 |
DisclosureSEC source: 0001209191-21-001718 · doc4.xml · derivative · entry 3 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,583 Underlying: Common Stock · 9,583 shares Expires 2028-03-20 F3 · date: On May 1, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the "Performance Milestones"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares. F3 · shares: On May 1, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the "Performance Milestones"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares. F3 · derivative.exercise_date: On May 1, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the "Performance Milestones"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares. F3 · derivative.expiration_date: On May 1, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the "Performance Milestones"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 20:58 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 4,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001718 · doc4.xml · nonDerivative · entry 1 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 568 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2020. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 21:03 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $13.48 | $0.00 |
DisclosureSEC source: 0001209191-21-000584 · doc4.xml · derivative · entry 2 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,500 Underlying: Common Stock · 1,500 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 146,875 shares as of December 30, 2020. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 21:03 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 1,500 | $13.48 | $20,220.00 |
DisclosureSEC source: 0001209191-21-000584 · doc4.xml · nonDerivative · entry 1 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 857 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2020. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 17:27 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-20-006973 · doc4.xml · derivative · entry 3 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2030-03-01 F3 · derivative.exercise_date: This option was granted on March 2, 2020 with respect to 135,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 03, 2020 Filed Mar 4, 2020 17:27 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $13.48 | $0.00 |
DisclosureSEC source: 0000899243-20-006973 · doc4.xml · derivative · entry 2 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-01-02 F2 · balance_after: On January 3, 2017, the reporting person was granted an option to purchase 15,000 shares of common stock. The option vested based on the satisfaction of certain performance criteria. The performance criteria was met, resulting in the vesting of option as to 15,000 shares. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 16:15 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $18.09 | $0.00 |
DisclosureSEC source: 0001209191-19-044238 · doc4.xml · derivative · entry 1 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2029-07-31 F1 · derivative.exercise_date: This option was granted on August 1, 2019 with respect to 55,000 shares of Common Stock, with 25% vesting on August 1, 2020 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 06, 2019 Filed Mar 12, 2019 16:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | PurchaseCommon Stock | 4,250 | $15.50 | $65,875.00 |
DisclosureSEC source: 0001209191-19-018817 · doc4.xml · nonDerivative · entry 2 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Dev and Corp Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Read SEC document |
| March 06, 2019 Filed Mar 12, 2019 16:38 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | PurchaseCommon Stock | 3,250 | $16.00 | $52,000.00 |
DisclosureSEC source: 0001209191-19-018817 · doc4.xml · nonDerivative · entry 1 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Dev and Corp Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,250 Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 16:23 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 81,000 | $0.00 Strike: $14.58 | $0.00 |
DisclosureSEC source: 0001209191-18-063663 · doc4.xml · derivative · entry 1 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Dev and Corp Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires 2028-12-17 F1 · derivative.exercise_date: This option was granted on December 18, 2018 with respect to 81,000 shares of Common Stock, with 25% vesting on December 18, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 01, 2018 Filed May 2, 2018 16:35 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 23,500 | $0.00 Strike: $20.56 | $0.00 |
DisclosureSEC source: 0001209191-18-027373 · doc4.xml · derivative · entry 1 SCHIERMEIER ANDREW · CIK 0001738456 · EVP, Corporate Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2028-04-30 F1 · derivative.exercise_date: This option was granted on May 1, 2018 with respect to 23,500 shares of Common Stock, with 25% vesting on May 1, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.